{"protocolSection": {"identificationModule": {"nctId": "NCT00830076", "orgStudyIdInfo": {"id": "0431-110"}, "secondaryIdInfos": [{"id": "2009_521"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)", "officialTitle": "A Study to Assess the Effects of Co-Administration of Sitagliptin and Metformin on Incretin Hormone Concentrations"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-12-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-04-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-05-14", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-01-26", "studyFirstSubmitQcDate": "2009-01-26", "studyFirstPostDateStruct": {"date": "2009-01-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-09-29", "resultsFirstSubmitQcDate": "2011-09-29", "resultsFirstPostDateStruct": {"date": "2011-11-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-10", "lastUpdatePostDateStruct": {"date": "2017-05-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 18, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin + placebo metformin", "type": "EXPERIMENTAL", "interventionNames": ["Drug: sitagliptin phosphate", "Drug: Comparator: placebo metformin"]}, {"label": "Metformin + placebo sitagliptin", "type": "EXPERIMENTAL", "interventionNames": ["Drug: metformin hydrochloride", "Drug: Comparator: placebo sitagliptin"]}, {"label": "Sitagliptin + metformin", "type": "EXPERIMENTAL", "description": "Co-administration of sitagliptin and metformin", "interventionNames": ["Drug: sitagliptin phosphate", "Drug: metformin hydrochloride"]}, {"label": "Placebo sitagliptin + placebo metformin", "type": "PLACEBO_COMPARATOR", "description": "Co-administration of placebo to sitagliptin and placebo to metformin", "interventionNames": ["Drug: Comparator: placebo sitagliptin", "Drug: Comparator: placebo metformin"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin phosphate", "description": "Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.", "armGroupLabels": ["Sitagliptin + metformin", "Sitagliptin + placebo metformin"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "metformin hydrochloride", "description": "Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.", "armGroupLabels": ["Metformin + placebo sitagliptin", "Sitagliptin + metformin"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Comparator: placebo sitagliptin", "description": "Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.", "armGroupLabels": ["Metformin + placebo sitagliptin", "Placebo sitagliptin + placebo metformin"]}, {"type": "DRUG", "name": "Comparator: placebo metformin", "description": "Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.", "armGroupLabels": ["Placebo sitagliptin + placebo metformin", "Sitagliptin + placebo metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations", "description": "Meal was given 2 hours postdose. Blood samples for determination of active GLP-1 concentration were collected (4 hours postmeal) on Day 2 in each treatment period.", "timeFrame": "6 hours postdose (4 hours postmeal) on Day 2"}], "secondaryOutcomes": [{"measure": "\u03b2-cell Sensitivity", "description": "\u03b2-cell sensitivity was defined as the incremental post-prandial\n\n4-hour area under the curve (AUC) for insulin secretion rate (ISR) normalized by the incremental post-prandial 4-hour plasma glucose AUC.", "timeFrame": "6 hour post-dose (4 hour postmeal) on Day 2"}, {"measure": "Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations", "description": "Meal was given 2 hours postdose. Blood samples for determination of glucose concentration were collected (4 hours postmeal) on Day 2 in each treatment period.", "timeFrame": "6 hours postdose (4 hours postmeal) on Day 2"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female subjects must have a negative pregnancy test\n* Subject has type 2 diabetes and is not currently receiving treatment with an oral AHA agent, has not received such treatment for 3 months prior to study, and/or has not received more than 4 total weeks treatment with an oral AHA agent for 12 to 18 months prior to the study\n* Subject is a nonsmoker or has not smoked and/or used nicotine for at least 6 months\n\nExclusion Criteria:\n\n* Subject has a history of stroke, seizures, or major neurological disorders\n* Female subject is breastfeeding\n* Subject cannot refrain from use of any prescription or non-prescription drugs beginning 2 weeks prior to first dose of study drug\n* Subject consumes more than 3 alcoholic beverages per day\n* Subject consumes more than 6 caffeinated beverages per day\n* Subject has had major surgery, or has donated or lost 1 unit of blood within 4 weeks of screening\n* Subject has a history of cancer, except certain skin or cervical cancer or other cancers treated more than 10 years prior to screening\n* Subject has a history of multiple and/or severe allergies or intolerance to drugs or food", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "All Participants", "description": "Participants received four 2-day treatment regimens (sitagliptin + placebo metformin for 2 days, metformin + placebo sitagliptin for 2 days, co-administration of sitagliptin + metformin for 2 days, and placebo sitagliptin + placebo metformin for 2 days) with a 7-day washout between each treatment period."}], "periods": [{"title": "Sitagliptin + Placebo Metformin", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "7-day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Metformin + Placebo Sitagliptin", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "7-day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Sitagliptin + Metformin", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "7-day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Placebo Sitagliptin + Placebo Metformin", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "Participants received four 2-day treatment regimens (sitagliptin + placebo metformin for 2 days, metformin + placebo sitagliptin for 2 days, co-administration of sitagliptin + metformin for 2 days, and placebo sitagliptin + placebo metformin for 2 days) with a 7-day washout between each treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "17"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations", "description": "Meal was given 2 hours postdose. Blood samples for determination of active GLP-1 concentration were collected (4 hours postmeal) on Day 2 in each treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "picomolar", "timeFrame": "6 hours postdose (4 hours postmeal) on Day 2", "groups": [{"id": "OG000", "title": "All Participants", "description": "Participants received four 2-day treatment regimens (sitagliptin + placebo metformin for 2 days, metformin + placebo sitagliptin for 2 days, co-administration of sitagliptin + metformin for 2 days, and placebo sitagliptin + placebo metformin for 2 days) with a 7-day washout between each treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"title": "Sitagliptin + placebo metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.00", "lowerLimit": "4.53", "upperLimit": "7.94"}]}]}, {"title": "Metformin + placebo sitagliptin", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.09", "lowerLimit": "3.09", "upperLimit": "5.42"}]}]}, {"title": "Sitagliptin + metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.22", "lowerLimit": "5.45", "upperLimit": "9.55"}]}]}, {"title": "Placebo sitagliptin + placebo metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.55", "lowerLimit": "1.17", "upperLimit": "2.05"}]}]}]}, {"type": "SECONDARY", "title": "\u03b2-cell Sensitivity", "description": "\u03b2-cell sensitivity was defined as the incremental post-prandial\n\n4-hour area under the curve (AUC) for insulin secretion rate (ISR) normalized by the incremental post-prandial 4-hour plasma glucose AUC.", "populationDescription": "Beta-cell sensitivity was not calculated for 1 participant following the administration of sitagliptin alone and metformin alone due to missing insulin data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "(ng/min)/(mg/dL)*10^ -3", "timeFrame": "6 hour post-dose (4 hour postmeal) on Day 2", "groups": [{"id": "OG000", "title": "All Participants", "description": "Participants received four 2-day treatment regimens (sitagliptin + placebo metformin for 2 days, metformin + placebo sitagliptin for 2 days, co-administration of sitagliptin + metformin for 2 days, and placebo sitagliptin + placebo metformin for 2 days) with a 7-day washout between each treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"title": "Sitagliptin + placebo metformin, n=17", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.50", "lowerLimit": "11.89", "upperLimit": "32.00"}]}]}, {"title": "Metformin + placebo sitagliptin, n=17", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.71", "lowerLimit": "15.67", "upperLimit": "42.18"}]}]}, {"title": "Sitagliptin + metformin, n=18", "categories": [{"measurements": [{"groupId": "OG000", "value": "26.39", "lowerLimit": "16.18", "upperLimit": "43.05"}]}]}, {"title": "Placebo sitagliptin + placebo metformin, n=18", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.44", "lowerLimit": "9.46", "upperLimit": "25.19"}]}]}]}, {"type": "SECONDARY", "title": "Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations", "description": "Meal was given 2 hours postdose. Blood samples for determination of glucose concentration were collected (4 hours postmeal) on Day 2 in each treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "6 hours postdose (4 hours postmeal) on Day 2", "groups": [{"id": "OG000", "title": "All Participants", "description": "Participants received four 2-day treatment regimens (sitagliptin + placebo metformin for 2 days, metformin + placebo sitagliptin for 2 days, co-administration of sitagliptin + metformin for 2 days, and placebo sitagliptin + placebo metformin for 2 days) with a 7-day washout between each treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"title": "Sitagliptin + placebo metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.30", "lowerLimit": "30.51", "upperLimit": "54.08"}]}]}, {"title": "Metformin + placebo sitagliptin", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.33", "lowerLimit": "17.55", "upperLimit": "41.12"}]}]}, {"title": "Sitagliptin + metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.02", "lowerLimit": "8.24", "upperLimit": "31.81"}]}]}, {"title": "Placebo sitagliptin + placebo metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.02", "lowerLimit": "39.24", "upperLimit": "62.81"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "43 days (four 2-day treatment periods, a 7-day washout interval between each treatment period, and approximately 14 days following the last dose of study treatment)", "eventGroups": [{"id": "EG000", "title": "Sitagliptin + Placebo Metformin", "description": "Participants received sitagliptin + placebo metformin for 2 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 4, "otherNumAtRisk": 18}, {"id": "EG001", "title": "Metformin + Placebo Sitagliptin", "description": "Participants received metformin + placebo sitagliptin for 2 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 3, "otherNumAtRisk": 18}, {"id": "EG002", "title": "Sitagliptin + Metformin", "description": "Participants received co-administration of sitagliptin + metformin for 2 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 3, "otherNumAtRisk": 18}, {"id": "EG003", "title": "Placebo Sitagliptin + Placebo Metformin", "description": "Participants received placebo sitagliptin + placebo metformin for 2 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 4, "otherNumAtRisk": 18}], "otherEvents": [{"term": "Iron Deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Conjunctival haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Vessel puncture site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Subcutaneous abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 18}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M8866", "name": "Gastric Inhibitory Polypeptide", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}